Abiraterone acetate
CAT:
804-HY-75054-03
Size:
50 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Abiraterone acetate
- CAS Number: 154229-18-2
- UNSPSC Description: Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
- Target Antigen: Cytochrome P450
- Type: Reference compound
- Related Pathways: Metabolic Enzyme/Protease
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/Abiraterone-acetate.html
- Purity: 99.96
- Solubility: DMSO : 10 mg/mL (ultrasonic)
- Smiles: O=C(O[C@@H]1CC2=CC[C@]3([H])[C@]([H])(CC[C@](C)(C(C4=CN=CC=C4)=CC5)[C@]35[H])[C@@]2(C)CC1)C
- Molecular Weight: 391.55
- References & Citations: [1]Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400.|[2]Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82.|[3]Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9.|[4]Lee GT, et al. Intracrine androgen biosynthesis in renal cell carcinoma. Br J Cancer. 2017 Mar 28;116(7):937-943.|[5]A O'Donnell, et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancervolume 90, pages2317–2325 (2004)
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: Launched